Johnson & Johnson has entered into a definitive agreement to acquire V-Wave, a privately held company that develops innovative treatment options for patients with heart failure.
Johnson & Johnson will make an upfront payment of $600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to some $1.1 billion.
V-Wave will become a part of Johnson & Johnson MedTech.
Most Read Medical News:
- FDA Approves 'Mask-Free' Sleep Apnea Treatment Device
- FDA Clears At-Home Sleep Apnea Test Patch
- Total Artificial Heart Implanted in First Human Patient
- Mayo Clinic Offers New Therapy to Treat Atrial Fibrillation
The acquisition will extend Johnson & Johnson MedTech's position in the cardiovascular market and accelerate the company's shift into high-growth, high-opportunity markets. The deal will also improve the company's relationship with structural interventional cardiologists and heart failure specialists.
V-Wave's cardiovascular implant technology specifically targets heart failure with reduced ejection fraction (HFrEF). In HFrEF, a patient's heart muscle can't properly pump blood containing oxygen and nutrients to the body. V-Wave's Ventura® Interatrial Shunt (IAS) is a novel implantable device designed to decrease elevated left atrial pressure in congestive heart failure by creating a shunt between the left and right atrium, reducing cardiovascular events and heart failure hospitalizations.
The device is placed in the heart through a minimally invasive catheter-based procedure and has the potential to fill a significant treatment gap between guideline directed medical therapies (GDMT) as a first line therapy and highly invasive cardiac replacement therapies, including left ventricular assist devices (LVADs) and heart transplantation.
The device received FDA Breakthrough Device Designation in 2019 and the CE mark in 2020 and can potentially be the first device of its kind to market.
According to the company, the implant addresses a need for approximately 800,000 patients who experience HFrEF in the U.S. every year, representing a market opportunity for significant sustainable growth and meaningful impact.
Click here to subscribe to our daily newsletter featuring breaking medical design engineering industry news.
